iBio - IBIO Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iBio in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IBIO shares.
View IBIO analyst ratings or view top-rated stocks.

2 analysts have issued 1 year target prices for iBio's stock. Their IBIO share price forecasts range from $37.50 to $37.50. On average, they anticipate the company's stock price to reach $37.50 in the next twelve months. This suggests a possible upside of 2,637.2% from the stock's current price.
View analysts price targets for IBIO or view top-rated stocks among Wall Street analysts.

iBio saw a increase in short interest in December. As of December 30th, there was short interest totaling 1,080,000 shares, an increase of 18.2% from the December 15th total of 913,500 shares. Based on an average trading volume of 445,400 shares, the days-to-cover ratio is presently 2.4 days. Approximately 10.5% of the shares of the stock are sold short.
View iBio's Short Interest.

iBio, Inc. (NYSEAMERICAN:IBIO) announced its quarterly earnings data on Monday, November, 15th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.25) by $0.25. The biotechnology company had revenue of $0.21 million for the quarter. iBio had a negative trailing twelve-month return on equity of 74.73% and a negative net margin of 2,004.10%.

Shares of iBio reverse split before market open on Tuesday, October 11th 2022. The 1-25 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia Oyj (NOK) and Moderna (MRNA).

iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

iBio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Eastern Capital Ltd, James P Mullaney, Robert L Erwin and Robert Matthew Lutz.
View institutional ownership trends.

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IBIO stock can currently be purchased for approximately $1.37.

iBio (NYSEAMERICAN:IBIO) has a market capitalization of $12.34 million and generates $2.38 million in revenue each year. The biotechnology company earns $-50,300,000.00 in net income (profit) each year or ($3.75) on an earnings per share basis.

iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The official website for the company is www.ibioinc.com. The biotechnology company can be reached via phone at (979) 446-0027, via email at ir@ibioinc.com, or via fax at 302-356-1173.